Case Reports in Oncological Medicine最新文献_第8页

Reporting a Case of Solid Pseudopapillary Neoplasm of the Pancreas in a 44-Year-Old Woman with Parallel Analysis of Literature. 报告一例44岁女性胰腺实性假乳头状肿瘤并文献平行分析。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/1768926

Sargun Singh, Qing Zhao, Teviah E Sachs, Kevan Hartshorn

引用次数: 0

Malignant Melanoma Presenting as Spinal Cord and Pleural Lesions. 恶性黑色素瘤表现为脊髓和胸膜病变。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/9647892

Aysha Albastaki, Sharifa Ahmed, Asher Khan, Abeer Farhan, Talal Almayman

引用次数: 0

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer. 药物在控制铂耐药透明细胞卵巢癌复发中的作用。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/2079654

Woraporn Sinsuwan, Phawit Norchai

{"title":"Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer.","authors":"Woraporn Sinsuwan, Phawit Norchai","doi":"10.1155/2023/2079654","DOIUrl":"https://doi.org/10.1155/2023/2079654","url":null,"abstract":"Background: Recurrent platinum-resistant clear-cell ovarian cancer has a low overall survival duration of 7-8 months, making it a fatal disease. Currently, chemotherapy is the major kind of treatment, but it offers little advantage. Repurposed conventional drugs have recently been found to offer the ability to control cancer with few side effects and at a reasonable cost to healthcare organizations. Case Presentation. In this case report, we present the case of a 41-year-old Thai female patient diagnosed with recurrent platinum-resistant clear-cell ovarian cancer (PRCCC) in the year 2020. After undergoing chemotherapy for two courses and failing to respond to treatment, she began alternative medicine with repurposing drugs in November 2020. Simvastatin, metformin, niclosamide, mebendazole, itraconazole, loratadine, and chloroquine were also administered. Two months after therapy, a computerized tomography (CT) scan revealed a conflict between a decline in tumor marker levels (CA 125, CA 19-9) and an increase in the number of lymph nodes. However, after continuing all medications for 4 months, the CA 125 level decreased from 303.6 to 54 U/ml, and the CA 19-9 level decreased from 1210.3 to 386.10 U/ml. The patient's EQ-5D-5L score increased from 0.631 to 0.829 (abdominal pain and depression), indicating improved quality of life. Overall survival was 8.5 months, and progression-free survival was 2 months.Conclusion: The response to drug repurposing is demonstrated by a four-month-long improvement in symptoms. This work introduces a novel strategy for the management of recurrent platinum-resistant clear-cell ovarian cancer that needs further evaluation in large-scale studies.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2023 ","pages":"2079654"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10028782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of Merkel Cell Carcinoma in a Patient Receiving Rituximab. 接受利妥昔单抗的患者发生默克尔细胞癌。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-11-03 eCollection Date: 2022-01-01 DOI: 10.1155/2022/1814338

Bana Antonios, Ujjwal Karki, Kais Antonios, Bipin Ghimire, Mohammad Muhsin Chisti

{"title":"Development of Merkel Cell Carcinoma in a Patient Receiving Rituximab.","authors":"Bana Antonios, Ujjwal Karki, Kais Antonios, Bipin Ghimire, Mohammad Muhsin Chisti","doi":"10.1155/2022/1814338","DOIUrl":"https://doi.org/10.1155/2022/1814338","url":null,"abstract":"Merkel cell carcinoma (MCC) is a rare, rapidly growing, and aggressive dermatological neoplasm. It is commonly reported in Caucasian ethnicities, and almost 50% of the patients have a concomitant malignancy and are on immunosuppressive chemotherapy. Here, we present a 79-year-old woman with a history of relapsed Stage II, grade III follicular lymphoma, receiving maintenance rituximab infusions. She presented with a raised erythematous papule on her left cheek. An excisional biopsy of the lesion confirmed a diagnosis of Merkel cell carcinoma. After which, she underwent a wider excision with 1-2 cm margins. PET scan did not reveal any FDG-avid uptake lesions that would be concerning for metastatic disease. However, she underwent a sentinel lymph node biopsy which was also negative. Thus, the diagnosis was finalized as Stage I (T1 N0 M0) MCC. There are only two reported cases in literature about the significant progression of Merkel cell carcinoma in patients who coincidentally were receiving rituximab as a part of treatment for another disease. This raises questions for future investigation and research on whether there is a direct association between rituximab use specifically and the rapid growth of MCC.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":" ","pages":"1814338"},"PeriodicalIF":0.9,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40471622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Acute Adrenal Hemorrhage as the Initial Manifestation of Metastatic Lung Adenocarcinoma: A Cautionary Tale. 急性肾上腺出血是转移性肺腺癌的最初表现:一个警世故事。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-10-25 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2864773

Sowbharnika Arivazhagan, Guru Prasad Parthiban, Christina Patterson, Karthik Reddy

引用次数: 0

A South African Breast Implant-Associated Anaplastic Large Cell Lymphoma: Clinical Presentation and Six-Year Follow-Up 一例南非乳房植入相关的整形不全大细胞淋巴瘤的临床表现和六年随访

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-05-31 DOI: 10.1155/2022/4162832

Alexandra Grubnik, Y. Ramdas, Barend Van der Bergh, S. Nayler, C. Benn, B. Rapoport

{"title":"A South African Breast Implant-Associated Anaplastic Large Cell Lymphoma: Clinical Presentation and Six-Year Follow-Up","authors":"Alexandra Grubnik, Y. Ramdas, Barend Van der Bergh, S. Nayler, C. Benn, B. Rapoport","doi":"10.1155/2022/4162832","DOIUrl":"https://doi.org/10.1155/2022/4162832","url":null,"abstract":"Breast augmentation is the most common surgical procedure for women globally, with 1,795,551 cases performed in 2019. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is highly uncommon, with 733 reported cases as of January 2020. In South Africa, there are less than 4000 breast augmentation surgeries annually. This case presents the first case report documentation of a South African woman diagnosed with BIA-ALCL. The patient was a 61-year-old woman who consulted the Breast Care Centre of Excellence in Johannesburg in 2015. She had a prior history of bilateral augmentation mammoplasty with subsequent implant exchange. The patient presented with periprosthetic fluid with a mass-like enhancement on the left breast. Aspiration of the mass-like fluid was positive for CD45, CD30, and CD68 and negative for CD20 and ALK-1, indicative of BIA-ALCL. Surgical treatment included bilateral explantation, complete capsulectomies, and bilateral mastopexy. Macroscopic examination of the left breast capsulectomy demonstrated fibrous connective tissue. The histological examination of the tumor showed extensive areas of broad coagulative necrosis with foamy histiocytes. Immunohistochemistry examination of this tumor showed CD3-, CD20-, and ALK-1-negative and CD30- and CD68-positive stains. PCR analysis for T-cell clonality showed monoclonal T-cell expansion. These findings confirm the presence of BIA-ALCL. The patient recovered well after surgery and did not require adjuvant therapy. A patient with a confirmed diagnosis of BIA-ALCL was successfully treated with explantation and complete capsulectomy. She was followed up regularly for six years, and the patient remains well and in remission.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48549141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical Treatment of Single Pontomedullary Junction Metastasis from Lung Cancer 癌症单桥髓核交界转移的外科治疗

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-05-31 DOI: 10.1155/2022/4041506

P. Missori, S. Peschillo, A. Ambrosone, A. Currà, S. Paolini

引用次数: 0

A Rare Case of Pure Primary Large Cell Neuroendocrine Carcinoma of the Gallbladder 罕见的单纯原发性胆囊大细胞神经内分泌癌

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-05-21 DOI: 10.1155/2022/6956046

R. Shackelford, E. Ozluk, J. Abdulsattar, T. Lairmore, Quyen Chu, E. Wei

引用次数: 0

A Pulmonary Zebra: Adult Primary Pulmonary Synovial Sarcoma 肺斑马:成人原发性肺滑膜肉瘤

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-04-16 DOI: 10.1155/2022/8649540

Sheffield Sandra, Nwachukwu Chidi, Ashby Tracy

引用次数: 0

A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim 检查点抑制剂治疗和培非司汀治疗后罕见的大血管血管炎

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-02-23 DOI: 10.1155/2022/7295305

J. Mort, Shipra Maheshwari, Nayanika Basu, P. Dillon, Kevin Brady, H. Bear, T. Millard

{"title":"A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim","authors":"J. Mort, Shipra Maheshwari, Nayanika Basu, P. Dillon, Kevin Brady, H. Bear, T. Millard","doi":"10.1155/2022/7295305","DOIUrl":"https://doi.org/10.1155/2022/7295305","url":null,"abstract":"Checkpoint inhibitors (CPIs) and pegfilgrastim, a long-acting growth factor agent, are vital components of current cancer treatments. Immune-related adverse events (irAEs) such as colitis and pneumonitis are well-established toxicities associated with CPI therapy. However, large-vessel vasculitis secondary to CPI utilization is reported only in rare case reports and case series. Interestingly, large-vessel vasculitis has also been reported as a rare complication of pegfilgrastim use. We present a 59-year-old female with left stage IIA (cT2N0M0) triple-negative breast cancer receiving neoadjuvant decitabine and pembrolizumab prior to neoadjuvant chemotherapy (NAC). NAC included standard-of-care dose dense doxorubicin and cyclophosphamide (ddAC) supported with pegfilgrastim use followed by weekly carboplatin and paclitaxel. After receiving her second cycle of ddAC with pegfilgrastim, the patient reported five days of left shoulder and arm pain. Subsequent CT imaging demonstrated wall thickening and inflammatory changes surrounding the left subclavian artery, aortic arch, left carotid artery, proximal innominate arteries, and the mid internal carotid arteries and its branching vessels. These findings were extremely concerning for large-vessel vasculitis. Excluding CPI therapy and pegfilgrastim use, no additional inciting event or medication that the patient was exposed to was noted to be associated with large-vessel vasculitis. We present this case to report on this rare but severe complication from commonly utilized agents in cancer treatment. We also extend the possibility of large-vessel vasculitis development in relation to the COVID-19 vaccine due to shared ingredients found in both the vaccine and pegfilgrastim. It is important to outline the treatment used for such a complication as no standardized treatment has been established for large-vessel vasculitis caused by CPI therapy or pegfilgrastim use.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42912710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3